

Review of Leishmaniasis: A Deep Dive into Parasite Biology, Clinical Manifestations, and Future Prospects for Treatment and Vaccines

Dunia Abed Hussein Al-Tikrity ¹

Abstract

The protozoan parasites from the *Leishmania* genus cause Leishmaniasis which continues to affect many regions because of its multiple clinical presentations along with difficult epidemiology patterns and insufficient treatment methods. Visceral leishmaniasis (VL) stands as the most dangerous form of this disease but cutaneous lesions (CL) represent less severe cases while all forms of leishmaniasis are influenced by *Leishmania* species and host immunity and HIV coinfections. The combination of shifting medical statistics because of climate change and human population shifts and social economic conditions is worsen global health problems particularly within areas where the disease is endemic. The complete relationship between *Leishmania* parasites and their host defense mechanisms alongside mechanisms of immune escape and prolonged infection is essential to study disease development and future therapeutic methods. The current best treatment of liposomal amphotericin B works well yet its effectiveness is hampered by drug resistance alongside toxicity and limited supply issues. Accomplished understanding of parasite virulence elements together with new combination chemotherapy strategies create better prospects for improved medical outcomes. Extensive research has failed to produce an authorized human vaccine for this tropical disease therefore additional research for vaccine development and better diagnostic tools and therapeutic methods becomes essential to control and eliminate it.

Keywords: Leishmaniasis, Cutaneous leishmaniasis (CL), Visceral leishmaniasis (VL), *Leishmania* parasites, Host-parasite interaction, Immune evasion, Drug resistance, Liposomal amphotericin B, Vaccine development, Chemoimmunotherapy, Epidemiology, Neglected tropical diseases (NTDs).

¹ Department of Biology, College of Education for Women, University of Tikrit

1. Introduction

The complex group of vector-borne diseases known as leishmaniasis exists globally because of different protozoan species from *Leishmania* genus. The leishmaniasis infection exists across two distinct forms namely cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL) while presenting diverse clinical features that result from interactions between the parasite species and human immune system [1]. Leishmaniasis prevalence has expanded throughout 98 countries according to recent epidemiological data and climate changes and human migration patterns represent potential sources of further disease spread [2].

The authors in [3] examine the detailed immune system evasion strategies of *Leishmania* parasites which allow them to establish infections and lead to possible disease reactivation following initial infections. The way *Leishmania* modifies its host controls how diseases advance in addition to how seriously they affect patients especially those with weak immune systems. The identification of parasite-host interactions forms the basis for building effective treatment methods especially in light of dual infections such as HIV-*Leishmania* [2].

Leishmaniasis therapy entails challenging treatment conditions which include standard drugs that come with important side effects and growing drug resistance patterns [4]. The search for new efficient and secure antileishmanial drugs remains essential because numerous treatments like amphotericin B presently exist [5]. People who undergo chemoimmunotherapy-based treatments may improve their current therapy results by using their immune system responses [4]. The newer understanding of *Leishmania* virulence factors together with their involvement in disease development opens new avenues for scientific research and therapeutic development [6]. The comprehension of molecular interactions helps scientists to understand disease mechanisms while shaping vaccine development approaches since no licensed vaccine exists for human use [7].

Researchers agree on the necessity to develop complete leishmaniasis prevention methods that combine better diagnostic capabilities with treatment solutions along with vaccine prospects. According to references [8] researchers need to tackle existing issues in treatment development while investigating modern therapeutic approaches which would help manage neglected tropical diseases specifically in endemic areas. Research findings from multiple studies show that leishmaniasis exhibits multiple characteristics which require continued scientific investigation into this worldwide health problem.

2. Literature review

The newer understanding of *Leishmania* virulence factors together with their involvement in disease development opens new avenues for scientific research and therapeutic development [6]. The comprehension of molecular interactions helps scientists to understand disease mechanisms while shaping vaccine development approaches since no licensed vaccine exists for human use [7].

Researchers agree on the necessity to develop complete leishmaniasis prevention methods that combine better diagnostic capabilities with treatment solutions along with vaccine prospects. According to references [8] researchers need to tackle existing issues in treatment development while investigating modern therapeutic approaches which would help manage neglected tropical diseases specifically in endemic areas. Research findings from multiple studies show that leishmaniasis exhibits multiple characteristics which require continued scientific investigation into this worldwide health problem.

The publication analyzes in great depth the complicated relationship between *Leishmania* parasites and their host immune system functions. The authors analyze the immune system evasion approaches obligate intracellular parasites use that result in different clinical leishmaniasis presentations.

A key point in this article explains that the host immune system plays a decisive role in determining how leishmaniasis develops. Various immune-related genetic polymorphisms determine the disease severity in leishmaniasis according to the authors. The research shows how genetic conditions of the individual body determine leishmaniasis pathogenesis which results in different forms ranging from cutaneous

leishmaniasis to visceral leishmaniasis. The article establishes that Cutaneous Leishmaniasis exists more commonly but Visceral Leishmaniasis presents the greater health threat because it proves lethal without proper treatment. [15][16]

The authors describe in detail how *Leishmania* creates a life cycle inside the human body starting from promastigote to amastigote formations inside macrophages. The critical adaptation enables parasites to survive in acetic temperature zones which also present elevated heat levels. The article presents a valuable analysis about how sand fly saliva enables the onset of infection. Research proves that saliva from sand flies activates inflammatory processes which help phagocytes enter the infection site to allow parasitic interactions with the immune system. [17][18][19]

The research evaluates how complement takes on a dual function when battling *Leishmania* infections. The authors emphasize that complement-mediated lysis destroys parasites but opsonization unintentionally makes *Leishmania* easier for phagocytes to take up which extends their survival. The reader acquires deeper comprehension of *Leishmania*'s complex infection dynamics because of such detailed knowledge about its immune evasion methods and the protective function of the lipophosphoglycan (LPG) coating on pathogens. [20][21]

The article "*Leishmania* Spp-Host Interaction: There Is Always an Onset, but Is There an End?" The paper authored by Conceição-Silva and Morgado [2] establishes a complete understanding of *Leishmania* parasite-host relationships through their in-depth examination of leishmaniasis disease manifestations. The review gains special importance because leishmaniasis impacts 98 countries with its health burden while suffering from influences caused by climate change and shifting populations.

The authors provide detailed descriptions of leishmaniasis-related clinical indicators which include cutaneous and mucosal lesions alongside the fatal visceral leishmaniasis (VL) and its designation as a priority attention illness by the World Health Organization (WHO). WHO established this disease class due to death rates from leishmaniasis as well as advanced epidemiological patterns especially among HIV co-infected populations who face compounded influences from malnutrition and existing conditions [2]. [22][23]

The article dedicates significant attention to the parasite-host relationship because authors explain this Biology as the basis for evaluating disease advancement and disease severity. The article demonstrates that *Leishmania* spp. uses developed immune evasion techniques to avoid detection by the host immune system which includes escaping neutrophil extracellular traps and modifying both macrophage and lymphocyte cellular activities. The continuous interaction between *Leishmania* spp and the host biology can result in either stable equilibrium or unstable disequilibrium states allowing severe disease symptoms to develop. The authors support their argument through mold and mucosal lesion development following primary cutaneous infections and Post-Kal-azar dermal leishmaniasis occurrence after VL recovery in the host [2]. [24][25]

The article considers diagnostic test development crucial by identifying rK39 serology as an effective method for identifying visceral leishmaniasis. Reliable diagnosis needs to happen immediately because it determines how patients receive treatment for leishmaniasis. A thorough evaluation of parasite-host dynamics will enable researchers to create better therapeutic and diagnostic methods as part of the solution to this public health problem according to the authors. [26]

Researchers question whether we should use immune system reactions to enhance therapeutic drug treatments in Leishmaniasis patients according to the article. The article written by Aruleba et al. [4] presents an entire view of leishmaniasis by presenting the disease as a neglected tropical disease as well as describing its treatment difficulties. The research presents evidence that leishmaniasis creates a substantial global health problem as the disease infests 2 million individuals each year and produces from benign cutaneous to life-threatening visceral outcomes. [27]

The article stresses how drug development for leishmaniasis began in the 1950s with medications which

have continued serving as main treatment methods for many years according to the authors' content. Drug development for Leishmaniasis remains stagnant because medical agencies do not give it the same funding and prioritization levels as malaria tuberculosis and HIV AIDS. Public health faces serious implications from this neglect along with the high threat of leishmaniasis in endemic areas according to the authors. [28][29]

The research conducted by Aruleba et al. [4] studies the relationship between currently used leishmanial drugs with host immune systems thus opening avenues for developing better treatment methods. The use of chemoimmunotherapeutic approaches stands out because simultaneous immune modulating and drug efficacy enhancement creates a promising therapeutic approach. This scientific concept aligns with current trends in infectious disease treatment because combining immunological techniques with standard therapies produces better results. [30]

The article establishes three distinct clinical forms of leishmaniasis as cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL) being essential to grasp different disease manifestations while guiding therapeutic approaches. The classification system shows why treatment must be adjusted according to particular disease manifestations. [31]

In their article "Insights into Leishmania Molecules and Their Potential Contribution to the Virulence of the Parasite" Ehab Kotb Elmahallawy and Abdulsalam A. M. Alkhaldi [6] give a thorough description of Leishmaniasis's biological foundation while discussing its important public health status with multiple forms of presentation and difficult treatment and prevention requirements. [31][27]

The authors stress Leishmaniasis arises due to the protozoan parasite Leishmania which spreads mostly through female sand fly insect bites. Knowledge about Leishmaniasis transmission using this vector plays a vital role in disease epidemiological studies because changing environmental factors create new endemic areas. Leishmaniasis affects 12 million people across the globe each year while resulting in many annual new cases and fatalities according to the article's data. [32]

The authors established Leishmaniasis includes three fundamental types which are cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL) and each corresponds to different Leishmania species. The different categories of Leishmaniasis need clinical recognition because they determine the required diagnosis procedures and treatment protocols. The health risks from MCL and VL cases exceed those of CL making these two forms require advanced medical interventions. [33][27]

The key element in this article revolves around deciphering the virulence elements of Leishmania. The authors state that improved knowledge of vital virulence elements together with host immune response processes leads to better clinical outcome predictions. Reliable knowledge about virulence factors enables the creation of new therapies and vaccines for treatment development. Ongoing research into molecular aspects should continue because it aims to improve present treatment approaches and support upcoming vaccine development according to the authors. [34][35]

According to this article early discovery of cases and proper treatment serve as fundamental preventive measures to control the disease. Public health organizations worldwide use this theory to lower the occurrence and severity of Leishmaniasis nationally and internationally. [36]

The researchers from Kaye et al. [7] analyze the vaccine development problems for leishmaniasis in their article while describing its major public health implications across endemic zones. The authors stress leishmaniasis exists as an endemic disease which infects 95 countries and threatens 1 billion people throughout the world. The high level of risk emphasizes the need for immediate preventive measures because vaccination tests and epidemiological studies demonstrate its potential to work. [37]

The article explains how Leishmania parasites maintain an intricate relationship with phlebotomine sand flies and human beings. The authors note that nineteen sand fly species transmit different Leishmania species which renders universal vaccine development a challenging task. Leishmaniasis vaccine

development faces challenges because the disease affects different areas of the world and triggers two distinct disease categories that need separate vaccine solutions. Scientists prove that clinical manifestations of the disease stem from parasite species as well as host factors including malnutrition and co-infections and socio-economic conditions in a continuing cycle between poverty and disease. [38][39]

The article examines how leishmaniasis produces serious financial complications for affected households since Sudanese research shows that 75% of families spent considerable money treating visceral leishmaniasis. Preventive measures particularly vaccination represent a solution because they would reduce both health costs and economic expenses affecting exposed populations facing leishmaniasis infection. [40][41]

The authors investigate the enduring health consequences resulting from leishmaniasis because mental health problems receive sparse attention when people discuss this disease. The research indicates leishmaniasis has widespread consequences which extend past medical signs so vaccine development requirements should include both disease-specific immune responses and social health along with economic elements. [42][43]

The article "Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review" by Rajamanthrilage Kasun Madusanka, Hermali Silva, and Nadira D. Karunaweera [5] presents an extensive analysis of cutaneous leishmaniasis (CL) treatment complexities and the need for specific therapeutic approaches. [44]

The authors clearly describe the leishmaniasis epidemiological data which demonstrates global impact on 350 million people with 2 million new diagnoses per year. As a result the disease needs immediate attention in endemic areas because of its elevated importance to public health frameworks. The three different types of leishmaniasis need proper identification because their condition characteristics determine the therapeutic methods used for their treatment. The article demonstrates that CL exists as the primary leishmaniasis form because skin lesion development leads to severe morbidity including facial disfigurement and physical limitations. [45][33]

The narrative review examines current treatment options that consist of chemotherapy and cryotherapy together with thermotherapy as well as exploring the deficiencies each method contains. Pentavalent antimonials and amphotericin B have proven vital in managing CL treatment but their efficacy decreases because of how leishmania species react to the drugs and the current state of patients' immune systems. Such information demonstrates the need for deep comprehension of disease pathophysiology to develop better therapeutic outcomes. [46][47]

The article examines management difficulties of CL through an evaluation of drug resistance complications and prolonged treatment periods along with medication-associated side effects. The authors emphasize the necessity to develop new treatment methods which proved effective and economically feasible especially when considering the wide range of *Leishmania* species along with their different responses to current medical treatments. This demand for species-specific treatment approaches significantly advances the discussion on leishmaniasis because universal approaches prove ineffective. [33][46]

Rafael Rocha along with André Pereira and Carla Maia presented a comprehensive global review of non-endemic leishmaniasis in humans through their article "Non-Endemic Leishmaniasis Reported Globally in Humans between 2000 and 2021—A Comprehensive Review" [48]. The authors properly explain leishmaniasis as a condition that stems from protozoan agents of the *Leishmania* genus transported by phlebotomine sand flies. The experts divide leishmaniasis into two fundamental groups: visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) that affect different *Leishmania* species along with distinct disease presentations. [9][49]

The article reveals that leishmaniasis reaches epidemic levels because it affects over 12 million people within 98 countries together with their territories. The authors describe the annual incidence statistics

which show 50,000 to 90,000 cases of VL and 600,000 to 1 million cases of CL. Leishmaniasis represents a major public health problem in endemic areas based on the present epidemiological data. The disease burden exceeds reported numbers because these areas lack consistent reporting policies. The lack of consistent reporting methodologies in data collection produces vital challenges for evaluating leishmaniasis epidemiology and obstructs the development of adequate intervention strategies. [22][50]

The article demonstrates that leishmaniasis importation cases are increasing because people are traveling more and migrating to new regions. An increasing number of at-risk individuals pose serious health risks since non-endemic region residents may develop the disease after visiting endemic countries. The authors establish this matter within the global health context by discussing non-endemic regions' requirement for enhanced awareness alongside preventive strategies. [51][52]

The paper concentrates on leishmaniasis epidemiological aspects but implicitly demonstrates the critical requirement to advance treatments and vaccines. The dangerous nature of visceral leishmaniasis as an untreated illness demands continuous research to develop proper treatments alongside vaccine production efforts. Through its analysis the paper demonstrates the intricate nature of Leishmaniasis treatment and reinforces the necessity of handling its multiple features [53].

Pacheco-Fernandez et al. [8] examine in their article "Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps" the complicated aspects of leishmaniasis treatment affecting particularly low- and middle-income nations. The authors stress that currently available therapies prove inadequate because their adverse side effects prevent their effective use outside controlled hospital settings. Researchers find this restriction alarming because leishmaniasis affects patients differently depending on whether they develop mild self-regressing skin problems or life-threatening internal infections. [54]

The article delivers essential knowledge about Leishmania parasite evasion methods through their establishment within protective niches within host cells. The scientists examine how parasites use cellular safe havens to survive beyond the timeframe of chemotherapy. The parasites' ability to persist in the host creates substantial obstacles for therapeutic success thus demanding new treatment approaches. The paper presents research discoveries concerning Leishmania survival mechanisms by examining the cellular and metabolic and molecular effects of infection. The thorough study offers a solid foundation to analyze both the parasite persistence capabilities and new treatment improvement possibilities. [55][56]

3. Conclusion

The global medical problem of Leishmaniasis persists primarily because of its challenging epidemiological patterns and wide-ranging disease forms (CL and VL) together with restricted therapeutic treatments. The escalating prevalence of leishmaniasis because of population movement together with climate changes demands rapid development of proper diagnostic procedures and medical treatments and vaccine options. Thorough comprehension of Leishmania parasite immune evasion techniques remains necessary to create better medical treatments since these approaches prove particularly vital for individuals with weak immune systems and those also suffering from HIV together with Leishmania infections. The therapeutic advancement of liposomal amphotericin B has not solved the challenges of treatment complexities which include adverse drug reactions and parasite drug resistance. Curing and ultimately eradicating neglected tropical disease requires sustained research involving chemoimmunotherapy along with parasite virulence factors assessment and development of modern vaccine approaches.

References:

1. S. P. Georgiadou, K. P. Makaritsis, and G. N. Dalekos, "Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment," 2015. ncbi.nlm.nih.gov
2. F. Conceição-Silva and F. N. Morgado, "Leishmania Spp-Host Interaction: There Is Always an Onset, but Is There an End?," 2019. ncbi.nlm.nih.gov

3. M. Rossi and N. Fasel, "How to master the host immune system? Leishmania parasites have the solutions!," 2017. ncbi.nlm.nih.gov
4. R. Taiwo Aruleba, K. C. Carter, F. Brombacher, and R. Hurdal, "Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?," 2020. ncbi.nlm.nih.gov
5. R. Kasun Madusanka, H. Silva, and N. D. Karunaweera, "Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review," 2022. ncbi.nlm.nih.gov
6. E. Kotb Elmahallawy and A. A. M. Alkhaldi, "Insights into Leishmania Molecules and Their Potential Contribution to the Virulence of the Parasite," 2021. ncbi.nlm.nih.gov
7. P. M. Kaye, S. Mohan, C. Mantel, M. Malhame et al., "Overcoming roadblocks in the development of vaccines for leishmaniasis," 2021. ncbi.nlm.nih.gov
8. T. Pacheco-Fernandez, H. Markle, C. Verma, R. Huston et al., "Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps," 2023. ncbi.nlm.nih.gov
9. M. M. Alcover, V. Rocamora, A. Ribas, R. Fisa et al., "Underestimation of Human Cutaneous Leishmaniasis Caused by Leishmania infantum in an Endemic Area of the Mediterranean Basin (Balearic Islands)," *Microorganisms*, 2023. mdpi.com
10. A. Aththanayaka and B. Dayananda, "Evolution of dirofilariasis diagnostic techniques from traditional morphological analysis to molecular-based techniques: a comprehensive review," *Frontiers in...*, 2024. frontiersin.org
11. A. N. Alsharksi, S. Sirekbasan, T. Gürkök-Tan, and A. Mustapha, "From Tradition to Innovation: Diverse Molecular Techniques in the Fight Against Infectious Diseases," *Diagnostics*, 2024. mdpi.com
12. R. J. Brüggemann and G. M. Jensen, "Liposomal amphotericin B—the past," *Journal of Antimicrobial*, vol. 2022. oup.com
13. X. Fu, C. Zhang, X. Lin, and X. Zheng, "Safety and effectiveness of high-dose liposomal amphotericin b: a systematic review and meta-analysis," *Altern. Ther. Health Med.*, vol. 2023. alternative-therapies.com
14. F. B. Cavassin, M. M. C. Magri, J. E. Vidal, F. A. M. C. Carlesse, et al., "Effectiveness, tolerability, and safety of different amphotericin b formulations in invasive fungal infections: a multicenter, retrospective, observational study," *Clinical Therapeutics*, 2024. [HTML]
15. DSSL Lera-Nonose, LF De Oliveira, et al., "Genetic variations in the human immune system influence susceptibility to tegumentary leishmaniasis: a systematic review and meta-analysis," *Expert Review of...*, vol. 2021, Taylor & Francis. [HTML]
16. C. Ye, L. Zhang, L. Tang, Y. Duan, J. Liu, "Host genetic backgrounds: the key to determining parasite-host adaptation," **Frontiers in Cellular and Molecular Biology**, vol. 2023. frontiersin.org
17. S. A. E. Soares, A. M. S. Marques, J. R. Carmo-Neto, "... Fixation and Staining of Infected Macrophages with Recovery of Promastigotes in Culture to Evaluate Phagocytosis and Amastigote Proliferation of Leishmania sp. in ...," *Acta Parasitologica*, 2025. [HTML]
18. P. de Almeida Machado, P. S. Gomes, E. S. Coimbra, et al., "Pretreatment with serine protease inhibitors impairs Leishmania amazonensis survival on macrophages," *Parasites & Vectors*, vol. 2025, Springer. springer.com
19. N. Eisenhuth, E. T. Rauh, M. Mitnacht, A. Debus, et al., "The histone methyltransferase DOT1B is dispensable for stage differentiation and macrophage infection of Leishmania mexicana," **Frontiers in Cellular**, 2025. frontiersin.org

20. E. S. Seow, "Analysis of the Interaction between Pentraxins and Leishmania Phosphoglycans," 2021. lshtm.ac.uk
21. R. S. Kaushal, N. Naik, M. Prajapati, et al., "Leishmania species: A narrative review on surface proteins with structural aspects involved in host–pathogen interaction," **Chemical Biology & Drug Design**, vol. 2023, Wiley Online Library. wiley.com
22. S. Sasidharan and P. Saudagar, "Leishmaniasis: where are we and where are we heading?," *Parasitology research*, 2021. [HTML]
23. W. Health Organization, "WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia," 2022. google.com
24. M. Chulanetra and W. Chaicumpa, "Revisiting the mechanisms of immune evasion employed by human parasites," *Frontiers in Cellular and Infection Biology*, vol. 11, 2021. frontiersin.org
25. R. Sabbahi, V. Hock, K. Azzaoui, and B. Hammouti, "Leishmania–sand fly interactions: exploring the role of the immune response and potential strategies for Leishmaniasis control," *Journal of Parasitic ...*, 2024. [HTML]
26. E. Iniguez and S. Kamhawi, "Discovery of new antigens for serodiagnosis of visceral leishmaniasis in humans and dogs adds valuable tools to our arsenal," *Mbio*, 2024. asm.org
27. S. Mann, K. Frasca, S. Scherrer, "A review of leishmaniasis: current knowledge and future directions," **Tropical Medicine Reports**, vol. 2021, Springer. springer.com
28. H. Zhang, R. Yan, Y. Liu, M. Yu, Z. He, and J. Xiao, "Progress in antileishmanial drugs: Mechanisms, challenges, and prospects," *PLOS Neglected Tropical Diseases*, vol. 19, no. 1, 2025. plos.org
29. S. Sundar, V. K. Singh, N. Agrawal, O. P. Singh, "Investigational new drugs for the treatment of leishmaniasis," **Investigational Drugs**, 2024. [HTML]
30. A. Kriaa, V. Mariaule, C. De Rudder, A. Jablaoui, et al., "From animal models to gut-on-chip: the challenging journey to capture inter-individual variability in chronic digestive disorders," *Gut*, vol. 2024, Taylor & Francis. tandfonline.com
31. B. A. Mathison and B. T. Bradley, "Review of the clinical presentation, pathology, diagnosis, and treatment of leishmaniasis," *Laboratory Medicine*, 2023. [HTML]
32. P. Cecílio, A. Cordeiro-da-Silva, and F. Oliveira, "Sand flies: Basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites," *Communications biology*, 2022. nature.com
33. H. J. C. de Vries and H. D. Schallig, "Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments," *American journal of clinical dermatology*, 2022. springer.com
34. D. Kumari, S. Mahajan, P. Kour, and K. Singh, "Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets," *Life sciences*, 2022. [HTML]
35. C. A. Grace, K. S. Sousa Carvalho, M. I. Sousa Lima, et al., "Parasite genotype is a major predictor of mortality from visceral leishmaniasis," **MBio**, vol. 2022. asm.org
36. M. Bamorovat and I. Sharifi, "Mutual role of patients and the healthcare system in the control of cutaneous leishmaniasis," **Transboundary and Emerging Diseases**, vol. 2023, Wiley Online Library. semanticscholar.org
37. M. C. Tarnas, A. Abbara, A. N. Desai, et al., "A study measuring the association between conflict,

- environmental factors, and annual global cutaneous and mucocutaneous leishmaniasis incidence (2005–2022),” *PLOS Neglected Tropical Diseases*, 2024. plos.org
38. V. O. Zorrilla, M. E. Lozano, L. J. Espada, and others, "Comparison of sand fly trapping approaches for vector surveillance of *Leishmania* and *Bartonella* species in ecologically distinct, endemic regions of Peru," *PLoS Neglected Trop. Dis.*, vol. 15, no. 6, 2021. plos.org
 39. E. Berriatua, P. Pérez-Cutillas, A. G. Vidal, and O. J. T. Briët, "The spatial relationship between leishmaniasis and sand flies in Europe and neighboring countries," *Parasites & Vectors*, 2024. springer.com
 40. A. O. Yousif, A. K. M. Idris, M. M. Awad, et al., "Out-of-pocket payments by end-stage kidney disease patients on regular hemodialysis: cost of illness analysis, experience from Sudan," **Hemodialysis International**, vol. 25, no. 4, pp. 500-507, 2021. [HTML]
 41. H. A. Hajomer, O. A. Elkhidir, S. O. Elawad, "The burden of end-stage renal disease in Khartoum, Sudan: cost of illness study," *Journal of Medical...*, vol. 2024, Taylor & Francis. tandfonline.com
 42. B. Merdekios, M. Shewangizaw, A. Sappo, E. Ewunetu, "Unveiling the hidden burden: Exploring the psychosocial impact of cutaneous leishmaniasis lesions and scars in southern Ethiopia," *PloS One*, 2025. plos.org
 43. D. L. Alderton, C. Ackley, and M. L. Trueba, "The psychosocial impacts of skin-neglected tropical diseases (SNTDs) as perceived by the affected persons: A systematic review," *PLOS Neglected Tropical Diseases*, vol. 2024. plos.org
 44. K. Chanda, "An overview on the therapeutics of neglected infectious diseases—Leishmaniasis and Chagas diseases," *Frontiers in Chemistry*, 2021. frontiersin.org
 45. I. Saini, J. Joshi, and S. Kaur, "Unwelcome prevalence of leishmaniasis with several other infectious diseases," *International Immunopharmacology*, 2022. [HTML]
 46. R. K. Madusanka, H. Silva, and N. D. Karunaweera, "Treatment of cutaneous leishmaniasis and insights into species-specific responses: a narrative review," *Infectious Diseases and ...*, vol. 2022, Springer. springer.com
 47. F. M. Abdoul-Latif, K. Oumaskour, N. Abdallah, A. Ainane, and others, "Overview of Research on Leishmaniasis in Africa: Current Status, Diagnosis, Therapeutics, and Recent Advances Using By-Products of the Sargassaceae Family," **Pharmaceuticals**, 2024. mdpi.com
 48. R. Rocha, A. Pereira, and C. Maia, "Non-Endemic Leishmaniasis Reported Globally in Humans between 2000 and 2021—A Comprehensive Review," 2022. ncbi.nlm.nih.gov
 49. H. Kato, "Epidemiology of Leishmaniasis: Risk factors for its pathology and infection," *Parasitology International*, 2025. [HTML]
 50. G. Pasquier, M. Demar, P. Lami, A. Zribi, "Leishmaniasis epidemiology in endemic areas of metropolitan France and its overseas territories from 1998 to 2020," *PLOS Neglected Tropical Diseases*, vol. XX, no. XX, pp. XX-XX, 2022. plos.org
 51. V. Tunalı and A. Özbilgin, "Knock, knock, knocking on Europe's door: Threat of leishmaniasis in Europe with a focus on Turkey," *Current Research in Parasitology & Vector-Borne Diseases*, vol. 2023, Elsevier. sciencedirect.com
 52. Y. Özbel, S. Töz, C. Muñoz, M. Ortuño, "The current epidemiology of leishmaniasis in Turkey, Azerbaijan and Georgia and implications for disease emergence in European countries," *Zoonoses and Public Health*, vol. 2022, Wiley Online Library. wiley.com
 53. A. Selvapandiyan, N. Puri, E. Reyaz, M. A. Beg, "Worldwide Efforts for the Prevention of Visceral Leishmaniasis Using Vaccinations," in **... and Solutions Against ...**, 2024, Springer. [HTML]

54. G. Grifferty, H. Shirley, J. McGloin, J. Kahn, "Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniasis: A Review," *Research and Reports in Tropical Medicine*, vol. 2021, Taylor & Francis, 2021. tandfonline.com
55. A. Valigurová and I. Kolářová, "Unrevealing the Mystery of Latent Leishmaniasis: What Cells Can Host Leishmania?," *Pathogens*, 2023. mdpi.com
56. J. C. R. Fernandes and D. S. Zamboni, "Mechanisms regulating host cell death during Leishmania infection," *Mbio*, 2024. asm.org